{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:56:09Z","timestamp":1794938169951,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grants\u2010in\u2010aid for Scientific Research","award":["200500887B"],"award-info":[{"award-number":["200500887B"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable disease course. The recent advancement of antifibrotic therapy has increased the need for reliable and specific biomarkers. This study aimed to assess alveolar epithelial biomarkers as predictors for the efficacy of the antifibrotic drug pirfenidone.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a post-hoc analysis of the prospective, multicenter, randomized, placebo-controlled, phase 3 trial of pirfenidone in Japan (total, n\u2009=\u2009267; pirfenidone, n\u2009=\u2009163; placebo, n\u2009=\u2009104). Logistic regression analysis was performed to extract parameters that predicted disease progression, defined by a\u2009\u2265\u200910% relative decline in vital capacity (VC) from baseline and\/or death, at week 52. For assessment of serum surfactant protein (SP)-D, SP-A and Krebs von den Lungen (KL)-6, all patients were dichotomized by the median concentration of each biomarker at baseline to the high and low biomarker subgroups. Associations of these concentrations were examined with changes in VC at each time point from baseline up to week 52, along with progression-free survival (PFS). Additionally, the effect of pirfenidone treatment on serial longitudinal concentrations of these biomarkers were evaluated.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In the multivariate logistic regression analysis, body mass index (BMI), %VC and SP-D in the pirfenidone group, and BMI and %VC in the placebo group were indicated as predictors of disease progression. Pirfenidone treatment reduced the decline in VC with statistical significance in the low SP-D and low SP-A subgroups over most of the treatment period, and also prolonged PFS in the low SP-D and low KL-6 subgroups. Furthermore, SP-D levels over time course were reduced in the pirfenidone group from as early as week 8 until the 52-week treatment period compared with the placebo group.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Serum SP-D was the most consistent biomarker for the efficacy of pirfenidone in the cohort trial of IPF. Serial measurements of SP-D might have a potential for application as a pharmacodynamic biomarker.<\/jats:p>\n<jats:p><jats:italic>Trial registration<\/jats:italic> The clinical trial was registered with the Japan Pharmaceutical Information Center (JAPIC) on September 13, 2005 (registration No. JapicCTI-050121; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/Clinicaltrials.jp\">http:\/\/Clinicaltrials.jp<\/jats:ext-link>)<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12931-020-01582-y","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T17:05:20Z","timestamp":1606755920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan"],"prefix":"10.1186","volume":"21","author":[{"name":"Pirfenidone Clinical Study Group in Japan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiyuki","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Nishikiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritaka","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Nukiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kudoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"issue":"2","key":"1582_CR1","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3-19.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1582_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1378\/chest.10-2572","volume":"140","author":"SD Nathan","year":"2011","unstructured":"Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest. 2011;140(1):221\u20139.","journal-title":"Chest"},{"issue":"7","key":"1582_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1164\/rccm.201403-0566OC","volume":"190","author":"M Natsuizaka","year":"2014","unstructured":"Natsuizaka M, Chiba H, Kuronuma K, Otsuka M, Kudo K, Mori M, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014;190(7):773\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1582_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-pathol-012513-104706","volume":"9","author":"PJ Wolters","year":"2014","unstructured":"Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol Mech Dis. 2014;9(1):157\u201379.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"6","key":"1582_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S2213-2600(15)00048-X","volume":"3","author":"RG Jenkins","year":"2015","unstructured":"Jenkins RG, Simpson JK, Saini G, Bentley JH, Russell AM, Braybrooke R, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med. 2015;3(6):462\u201372.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"1582_CR6","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","volume":"5","author":"TM Maher","year":"2017","unstructured":"Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017;5(12):946\u201355.","journal-title":"Lancet Respir Med"},{"key":"1582_CR7","first-page":"10","volume":"1","author":"L Organ","year":"2018","unstructured":"Organ L, Duggan AM, Oballa E, Taggart S, Simpson J, Kangombe A, et al. Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort. Respir Res. 2018;1:10.","journal-title":"Respir Res."},{"issue":"9779","key":"1582_CR8","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet. 2011;377(9779):1760\u20139.","journal-title":"Lancet"},{"issue":"22","key":"1582_CR9","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King","year":"2014","unstructured":"King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"153","key":"1582_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/16000617.0021-2019","volume":"28","author":"V Somogyi","year":"2019","unstructured":"Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, M\u00fcller V, Kreuter M. The therapy of idiopathic pulmonary fibrosis: What is next? Eur Respir Rev. 2019;28(153):1\u201320.","journal-title":"Eur Respir Rev"},{"issue":"8","key":"1582_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S2213-2600(18)30185-1","volume":"6","author":"M Neighbors","year":"2018","unstructured":"Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, et al. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. Lancet Respir Med. 2018;6(8):615\u201326.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"1582_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/S2213-2600(18)30234-0","volume":"6","author":"M Kreuter","year":"2018","unstructured":"Kreuter M, Maher T. Gazing into the crystal ball: can treatment response be predicted in IPF? Lancet Respir Med. 2018;6(8):570\u20132.","journal-title":"Lancet Respir Med"},{"key":"1582_CR13","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1177\/34.9.2426341","volume":"34","author":"SR Walker","year":"1986","unstructured":"Walker SR, Williams MC, Benson B. Immunocytochemical localization of the major surfactant apoproteins in type II cells, Clara cells, and alveolar macrophages of rat lung. J Histochem Cytochem. 1986;34:1137\u201348.","journal-title":"J Histochem Cytochem"},{"key":"1582_CR14","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1177\/40.10.1527377","volume":"40","author":"WF Voorhout","year":"1992","unstructured":"Voorhout WF, Veenendaal T, Kuroki Y, Ogasawara Y, van Golde LM, Geuze HJ. Immunocytochemical localization of surfactant protein D (SP-D) in type II cells, Clara cells, and alveolar macrophages of rat lung. J Histochem Cytochem. 1992;40:1589\u201397.","journal-title":"J Histochem Cytochem"},{"issue":"5","key":"1582_CR15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.resinv.2018.06.001","volume":"56","author":"H Chiba","year":"2018","unstructured":"Chiba H, Otsuka M, Takahashi H. Significance of molecular biomarkers in idiopathic pulmonary fibrosis: a mini review. Respir Investig. 2018;56(5):384\u201391.","journal-title":"Respir Investig"},{"issue":"4","key":"1582_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.trsl.2012.01.012","volume":"159","author":"R Vij","year":"2012","unstructured":"Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res. 2012;159(4):218\u201327.","journal-title":"Transl Res"},{"issue":"3","key":"1582_CR17","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1164\/ajrccm.162.3.9910080","volume":"162","author":"H Takahashi","year":"2000","unstructured":"Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000;162(3):1109\u201314.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1582_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1183\/09031936.02.00081102","volume":"19","author":"KE Greene","year":"2002","unstructured":"Greene KE, King JE, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002;19(3):439\u201346.","journal-title":"Eur Respir J"},{"key":"1582_CR19","first-page":"23","volume":"96","author":"K Wang","year":"2017","unstructured":"Wang K, Ju Q, Cao J, Tang W, Zhang J. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis. Med (United States). 2017;96:23.","journal-title":"Med (United States)"},{"issue":"10","key":"1582_CR20","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1164\/rccm.201505-0862OC","volume":"194","author":"ES White","year":"2016","unstructured":"White ES, Xia M, Murray S, Dyal R, Flaherty CM, Flaherty KR, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2016;194(10):1242\u201351.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1582_CR21","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.chest.2018.08.1083","volume":"154","author":"G Raghu","year":"2018","unstructured":"Raghu G, Richeldi L, Jagerschmidt A, Martin V, Subramaniam A, Ozoux ML, et al. Idiopathic pulmonary fibrosis: prospective, case-controlled study of natural history and circulating biomarkers. Chest. 2018;154(6):1359\u201370.","journal-title":"Chest"},{"issue":"SUPPL. 1","key":"1582_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1440-1843.2006.00809.x","volume":"11","author":"H Takahashi","year":"2006","unstructured":"Takahashi H, Shiratori M, Kanai A, Chiba H, Kuroki Y, Abe S. Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D. Respirology. 2006;11(SUPPL. 1):51\u20134.","journal-title":"Respirology"},{"issue":"6","key":"1582_CR23","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1378\/chest.08-2209","volume":"135","author":"BW Kinder","year":"2009","unstructured":"Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009;135(6):1557\u201363.","journal-title":"Chest"},{"issue":"5","key":"1582_CR24","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1378\/chest.11-2735","volume":"143","author":"JW Song","year":"2013","unstructured":"Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS. Blood biomarkers MMP-7 and SP-A: Predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013;143(5):1422\u20139.","journal-title":"Chest"},{"issue":"2","key":"1582_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1440-1843.2006.00834.x","volume":"11","author":"A Yokoyama","year":"2006","unstructured":"Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006;11(2):164\u20138.","journal-title":"Respirology"},{"issue":"6","key":"1582_CR26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1582_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.resinv.2018.03.003","volume":"56","author":"S Homma","year":"2018","unstructured":"Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig. 2018;56(4):268\u201391.","journal-title":"Respir Investig"},{"key":"1582_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.rmed.2017.08.021","volume":"131","author":"K Ikeda","year":"2017","unstructured":"Ikeda K, Shiratori M, Chiba H, Nishikiori H, Yokoo K, Saito A, et al. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respir Med. 2017;131:184\u201391.","journal-title":"Respir Med"},{"issue":"4","key":"1582_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1183\/09031936.00005209","volume":"35","author":"H Taniguchi","year":"2010","unstructured":"Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821\u20139.","journal-title":"Eur Respir J"},{"key":"1582_CR30","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","volume":"161","author":"American Thoracic Society","year":"2000","unstructured":"American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement: American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646\u201364.","journal-title":"Am J Respir Crit Care Med"},{"key":"1582_CR31","unstructured":"Clinical diagnostic and treatment guidance for idiopathic interstitial pneumonias. In Nankodo Edited by: Japanese Respiratory Society\u2019s Committee formulating diagnosis and treatment guideline for diffuse lung diseases. Tokyo. 2004;63\u20135. [in Japanese]."},{"issue":"1","key":"1582_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1465-9921-12-93","volume":"12","author":"H Taniguchi","year":"2011","unstructured":"Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: Extended analysis of the pirfenidone trial. Respir Res. 2011;12(1):93.","journal-title":"Respir Res"},{"issue":"1","key":"1582_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/1465-9921-12-143","volume":"12","author":"A Azuma","year":"2011","unstructured":"Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res. 2011;12(1):143.","journal-title":"Respir Res"},{"issue":"6","key":"1582_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.resinv.2015.06.002","volume":"53","author":"Y Taguchi","year":"2015","unstructured":"Taguchi Y, Ebina M, Hashimoto S, Ogura T, Azuma A, Taniguchi H, et al. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan. Respir Investig. 2015;53(6):279\u201387.","journal-title":"Respir Investig"},{"issue":"1","key":"1582_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12890-019-1042-0","volume":"20","author":"T Yoshikawa","year":"2020","unstructured":"Yoshikawa T, Otsuka M, Chiba H, Ikeda K, Mori Y, Umeda Y, et al. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;20(1):1\u201311.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"1582_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.resinv.2016.09.003","volume":"55","author":"K Wakamatsu","year":"2017","unstructured":"Wakamatsu K, Nagata N, Kumazoe H, Oda K, Ishimoto H, Yoshimi M, et al. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir Investig. 2017;55(1):16\u201323.","journal-title":"Respir Investig"},{"issue":"9","key":"1582_CR37","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.rmed.2013.06.011","volume":"107","author":"R Okuda","year":"2013","unstructured":"Okuda R, Hagiwara E, Baba T, Kitamura H, Kato T, Ogura T. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med. 2013;107(9):1431\u20137.","journal-title":"Respir Med"},{"issue":"1","key":"1582_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2466-14-196","volume":"14","author":"H Nishikiori","year":"2014","unstructured":"Nishikiori H, Chiba H, Ariki S, Kuronuma K, Otsuka M, Shiratori M, et al. Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2014;14(1):1\u201310.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"1582_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-10-111","volume":"10","author":"M Shigemura","year":"2012","unstructured":"Shigemura M, Nasuhara Y, Konno S, Shimizu C, Matsuno K, Yamguchi E, et al. Effects of molecular structural variants on serum Krebs von den Lungen-6 levels in sarcoidosis. J Transl Med. 2012;10(1):1\u201310.","journal-title":"J Transl Med"},{"issue":"5","key":"1582_CR40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00408-018-0140-8","volume":"196","author":"N Ronan","year":"2018","unstructured":"Ronan N, Bennett DM, Khan KA, McCarthy Y, Dahly D, Bourke L, et al. Tissue and bronchoalveolar lavage biomarkers in idiopathic pulmonary fibrosis patients on pirfenidone. Lung. 2018;196(5):543\u201352.","journal-title":"Lung"},{"issue":"9","key":"1582_CR41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S2213-2600(19)30255-3","volume":"7","author":"TM Maher","year":"2019","unstructured":"Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, et al. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med. 2019;7(9):771\u20139.","journal-title":"Lancet Respir Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01582-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-020-01582-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01582-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T17:33:39Z","timestamp":1606757619000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-020-01582-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1186\/s12931-020-01582-y","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"assertion":[{"value":"27 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the institutional review board at each center, and written informed consent was obtained from all participants prior to enrolment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate:"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication:"}},{"value":"KI, HC, HN, and HT have received grants, and TO has received personal fees from Shionogi & Co., Ltd. KI, HC, HN, TO, and HT have received grants, and HC, HN, AA, YK, TO, YT, and HT have received personal fees from Boehringer Ingelheim Co. HS and SM are employees of Shionogi & Co., Ltd. and own shares in the company. The other authors do not have any conflicts to declare (ME, MS, YS, TN, and SK).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests:"}}],"article-number":"316"}}